Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 19/20 | 0.63 |
| ▸ | FNTB | P49356 | 19/20 | 0.63 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16792190 | 1.00 | FNTA (0.63) | FNTAFNTBPGGT1B | |
| SCHEMBL7516854 | 1.00 | FNTA (0.63) | FNTAFNTBPGGT1B | |
| SCHEMBL7515310 | 0.95 | FNTA (0.56) | FNTAFNTBPGGT1B | |
| SCHEMBL9058006 | 0.94 | FNTA (0.57) | FNTAFNTBPGGT1B | |
| SCHEMBL8865579 | 0.94 | FNTA (0.71) | FNTAFNTBPGGT1B | |
| SCHEMBL8763874 | 0.94 | FNTA (0.55) | FNTAFNTBPGGT1B | |
| SCHEMBL8865467 | 0.93 | FNTA (0.53) | FNTAFNTBPGGT1B | |
| SCHEMBL8865456 | 0.93 | FNTA (0.53) | FNTAFNTBPGGT1B | |
| SCHEMBL8763043 | 0.92 | FNTA (0.67) | FNTAFNTBPGGT1B | |
| SCHEMBL8762235 | 0.92 | FNTA (0.64) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019529-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2002-09-11 | — | — | EP | claimed |
| JP-2001518281-A | — | — | 2001-10-16 | — | — | JP | claimed |
| EP-1019529-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| EP-1009854-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | claimed |
| WO-1999010525-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1999010523-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1996010034-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | claimed |
| EP-1019529-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6103487-A | DETECTING MODULATORS THAT SUPPRESS THE ACTIVITY OF A TRANSFERASES; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-1019529-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1019530-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1009854-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-2000016626-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-1999010525-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010524-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010523-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| US-5652257-A | ANTICARCINOGENIC | MERCK & CO., INC. (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0783517-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010034-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |